Directorio

We are doing this study to assess how accurately a medical device under test that can measure blood pressure and changes to blood pressure during surgery non-invasively. We want to compare its performance and accuracy to that of an arterial line, which is an invasive procedure.

Many people with HIV want to breastfeed their babies, but until recently, the rules in the U.S. didn't allow this. There's a small risk of passing HIV to the baby, but we need more information to understand this better. This research will make a list of babies and how they are fed, talk to families about why they choose certain ways to feed their babies, and test breast milk and blood to see if the HIV that can't be found in the blood is also not in the breast milk.

We are doing this study to find out if an experimental drug called abatacept (the study drug) is a safe and effective option to help prevent graft-versus-host (GVHD) disease for people who get an omidubicel hematopoietic stem cell transplant to treat blood cancer. Omidubicel is a recently approved (2023) stem cell transplantation that uses modified umbilical cord blood. This new method of stem cell transplantation helps patients' immune systems recover more quickly after intensive chemotherapy.

After joining the study, each person will have several checkups. These include the first visit, the ablation procedure, and a visit before going home. There will also be a phone call about one week later, a visit around one month later, and visits at three months, six months, and twelve months. These visits help doctors check how the heart is doing over time.

If you agree to be in the study, you will have 1 study visit that will last about 4 hours. The visit will include asking questions about your medical history, vital signs, pulmonary function tests (PFTs) and an MRI (magnetic resonance image) of the chest with inhaled Xenon gas. Someone from the study team will contact you about 24 hours after your study visit.

We are doing this study to analyze biomarker responses to different drug regimens used for people who have HER2- and HER2+ breast cancer. We hope what we learn from the study can help us develop better treatments and figure out which treatment option(s) will be best for breast cancer patients.

We are doing this study to find the most effective, safe dose of an experimental drug called IAM1363 (the study drug) for people who have advanced cancers harboring HER2 alterations.